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Summary
Background: Various treatment combinations of peginterferon (PEG‐IFN) and
nucleos(t)ide analogues have been evaluated for chronic hepatitis B (CHB), but the
optimal regimen remains unclear.
Aims: To study whether PEG‐IFN add‐on increases response compared to entecavir
(ETV) monotherapy, and whether the duration of ETV pretreatment influences
response.
Methods: Response was evaluated in HBeAg positive patients previously treated in
two randomized controlled trials. Patients received ETV pretreatment for at least
24 weeks and were then allocated to 24‐48 weeks of ETV+PEG‐IFN add‐on, or
continued ETV monotherapy. Response was defined as HBeAg loss combined with
HBV DNA <200 IU/mL 48 weeks after discontinuing PEG‐IFN.
Results: Of 234 patients, 118 were assigned PEG‐IFN add‐on and 116 continued
ETV monotherapy. Response was observed in 38/118 (33%) patients treated with
add‐on therapy and in 23/116 (20%) with monotherapy (P = 0.03). The highest
response to add‐on therapy compared to monotherapy was observed in PEG‐IFN
naive patients with HBsAg levels below 4000 IU/mL and HBV DNA levels below
50 IU/mL at randomization (70% vs 34%; P = 0.01). Above the cut‐off levels,
response was low and not significantly different between treatment groups. Dura-
tion of ETV pretreatment was associated with HBsAg and HBV DNA levels (both
P < 0.005), but not with response (P = 0.82).
Conclusions: PEG‐IFN add‐on to ETV therapy was associated with higher response
compared to ETV monotherapy in patients with HBeAg positive CHB. Response
doubled in PEG‐IFN naive patients with HBsAg below 4000 IU/mL and HBV DNA
below 50 IU/mL, and therefore identifies them as the best candidates for PEG‐IFN
add‐on (Identifiers: NCT00877760, NCT01532843).
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1 | INTRODUCTION
The achievement of functional cure for chronic hepatitis B (CHB)
infection remains difficult due to a persistent infection of hepato-
cytes with covalently closed circular DNA (cccDNA).1,2 CccDNA is a
minichromosome that serves as a transcription template for hepatitis
B virus (HBV) antigen and virion production. Nucleos(t)ide analogue
(NA) therapy only marginally reduces levels of cccDNA such that
cccDNA depletion would require years of NA treatment.3,4
NA therapy effectively suppresses the HBV up to 8 years with
few side‐effects, but serological response rates remain low. The dis-
continuation of NA therapy leads to frequent virological relapse and
patients therefore require long‐term, if not indefinite NA therapy.5–10
In contrast, a finite course of pegylated interferon (PEG‐IFN) achieves
more sustained immune response than NA therapy.9,11,12 PEG‐IFN is
also able to directly target cccDNA and induce cccDNA decline in
combination with NA therapy.13,14 PEG‐IFN monotherapy, however,
induces sustained response in only 30%‐40% of patients and has lim-
ited tolerability.15,16
These limitations of CHB therapy have led to the evaluation of
various treatment combinations of NAs and PEG‐IFN to maximise
response rates, among which is the strategy of adding PEG‐IFN to
NA treatment (PEG‐IFN add‐on). One of the rationales for the PEG‐
IFN add‐on strategy is that long‐term NA treatment enables partial
restoration of the liver‐specific immunology of both the adaptive (T‐
cells) and innate immune system (natural killer cells).17–20 Viral load
suppression could thus increase the immunomodulatory effect of
PEG‐IFN therapy resulting in increased HBsAg loss and HBeAg loss
or accelerated HBsAg decline rates.11
Several randomized controlled trials (RCT) employed a PEG‐IFN
add‐on strategy in HBeAg positive and negative patients on long‐
term NA monotherapy.21–23 PEG‐IFN add‐on increased HBeAg sero-
conversion and viral antigen decline, but primary efficacy endpoints
were not reached, possibly because of insufficient power or because
the effect was limited to a subgroup of patients only. Clinical prac-
tice could benefit substantially if these responsive patients can be
identified at the start of PEG‐IFN therapy with readily available labo-
ratory markers. Other remaining issues concern the optimal duration
of PEG‐IFN add‐on and of NA pretreatment.
We therefore evaluated whether PEG‐IFN add‐on to ETV treat-
ment increases serological response compared to ETV monotherapy
in CHB, and whether the duration of ETV pretreatment or the length
of PEG‐IFN addition therapy influenced response. To this purpose,
we performed an analysis in a large HBeAg positive CHB population
that was previously treated in two global RCTs.
2 | MATERIALS AND METHODS
2.1 | Combined study design
We conducted a post hoc analysis of two international RCTs (ARES
and PEGON; registered at ClinicalTrials.gov, Identifier: NCT00877760,
NCT01532843).21,23 Detailed inclusion and exclusion criteria have
been previously described. In short, patients with CHB were eligible if
they were HBeAg positive at randomization (baseline) and had a serum
alanine aminotransferase (ALT) between 1.3 and five times the upper
limit of normal (ULN). Patients had received pretreatment with ETV
for at least 6 months. The main exclusion criteria were history of
decompensated liver disease, coinfection with hepatitis C virus or HIV,
other concomitant liver disease, and any contra‐indication for inter-
feron therapy.
After initial treatment with ETV (Baraclude, Bristol‐Myers Squibb,
New York, NY, 0.5 mg once‐daily), patients were randomized to
either 6‐12 months of PEG‐IFN addition or of continued ETV
monotherapy (Figure 1). Patients treated within the ARES trial
received PEG‐IFN a2a (Pegasys, F. Hoffmann‐La Roche Ltd., Basel,
Switzerland, 180 μg once‐weekly) and patients in the PEGON study
PEG‐IFN a2b (PegIntron, Merck, Kenilworth, NJ, 1.5 μg/kg once‐
weekly). If patients achieved HBeAg seroclearance in combination
with an HBV DNA level below 200 IU/mL at the end of PEG‐IFN
treatment (EOT) or at the corresponding time point for patients allo-
cated to ETV monotherapy, ETV was discontinued after a minimum
of 24 weeks consolidation therapy. Otherwise, ETV was continued
until the end of follow‐up (EOF), which was 48 weeks after EOT for
all patients regardless of treatment response.
Several patients within the ARES study did not reach the desig-
nated primary endpoint at the end of treatment. These patients were
allowed to enrol in the subsequent PEGON trial and were then ran-
domized again to PEG‐IFN add‐on or ETV monotherapy. This study
was approved by local ethics boards of all centres and performed in
concordance with Good Clinical Practice guidelines and the Declara-
tion of Helsinki. All patients provided written consent.
2.2 | Study endpoints
Response was defined as combined HBeAg loss with HBV DNA
<200 IU/mL at EOF. We analysed the modified intention‐to‐treat
population, which includes all patients who received at least one
dose of the allocated treatment after baseline. Patients were consid-
ered non‐responders in case of missing HBeAg status or HBV DNA
at EOF. To assess the potential for functional cure, as studied with
therapeutic compounds now in development, we also investigated
specific other virological and serological outcomes (Table 2).
2.3 | Study follow‐up and measurements
During PEG‐IFN treatment, routine examination and laboratory test-
ing were performed every 4 weeks. After PEG‐IFN treatment was
stopped, patients visited the out‐patient clinic every 12 weeks until
EOF. Patients on ETV monotherapy had study visits every 12 weeks
throughout the entire study period. Routine biochemical and haema-
tological tests were assessed locally at every visit. Serum ALT levels
were standardised according to the ULN per centre and gender.
Serum HBV DNA was measured with the Cobas TaqMan 48 poly-
merase chain reaction assay (lower limit of detection: 20 IU/mL;
Roche Diagnostics, Basel, Switzerland). Serum HBeAg, anti‐HBe and
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HBsAg were evaluated with Architect (Abbott Laboratories, North
Chicago, IL) or Cobas Elecsys 411 (lower limit of detection 0.30 and
0.05 IU/mL, respectively; Roche Diagnostics). HBV genotyping was
performed with the INNO‐LiPA HBV genotype assay (Fujirebio Eur-
ope, Ghent, Belgium). If HBV genotype could not be assessed due to
undetectable HBV DNA levels at baseline, we reviewed HBV geno-
type data in medical charts where possible. The presence of cirrhosis
was defined by Ishak stage 6 on liver biopsy, or an aspartate amino-
transferase to platelet ratio index (APRI) score >1.0.24
2.4 | Statistical analysis
Variables are summarised with mean ± SD or frequency (%). Non‐nor-
mally distributed variables were log‐transformed. Differences in out-
comes were evaluated by chi‐squared test, Student's t‐test or Mann‐
Whitney test, where appropriate. To study the influence of PEG‐IFN
addition on response and adjust for confounders, we performed logistic
regression analysis. Predefined covariates included age, gender, HBV
genotype, cirrhosis, previous use of PEG‐IFN, duration of ETV pretreat-
ment, ALT, HBV DNA, and HBsAg. The duration of ETV pretreatment
and HBV DNA were categorised due to a skewed distribution. Predic-
tors that were significantly associated with response in univariable
regression (P < 0.10) were further evaluated in multivariable regres-
sion (backward stepwise selection). Interactions between response and
baseline variables included in the final model were explored.
Cut‐off values for HBV DNA and HBsAg at baseline were evalu-
ated to find clinically useful starting rules for PEG‐IFN add‐on.
HBsAg levels were dichotomised at thresholds between 2.7 and 5.0
log IU/mL in steps of 0.1. HBV DNA was categorised at 50, 100,
500, and 1000 IU/mL. The likelihood‐ratio test and sum of log‐likeli-
hood ratios of the two treatment groups were calculated. We
selected optimal cut‐off values based on a minimum response differ-
ence of 15% between add‐on and monotherapy; a significant likeli-
hood ratio test of add‐on vs monotherapy below the cut‐offs, but
not above; and the lowest sum of likelihood ratios. For each thresh-
old receiver operating characteristic curves were constructed and
AUCs were calculated and compared to each other. Furthermore, a
sensitivity analysis was performed among non‐responding patients
within the ARES study who subsequently received retreatment in
the PEGON study by modelling the correlated data in a generalised
estimating equation.25 Analyses were performed in SPSS (v. 22.0, Chi-
cago, IL) and SAS v. 11.2 (SAS Institute Inc, Cary, NC). Two‐sided
P < 0.05 were considered significant.
3 | RESULTS
3.1 | Patient population
A total of 234 patients met the inclusion criteria. Excluded were five
patients assigned PEG‐IFN add‐on and 10 assigned ETV monother-
apy who had achieved HBeAg loss at baseline (during ETV pretreat-
ment). At baseline, 118 patients were allocated to PEG‐IFN add‐on
and 116 patients continued ETV monotherapy. Baseline characteris-
tics were comparable between the two groups (Table 1). The mean
age was 33 (SD 9) years, the majority of patients were male and of
Asian ethnicity. HBV genotypes A/B/C/D/other were present in 4%,
17%, 41%, 24%, and 1% of patients, respectively. In total, 80/118
(68%) patients received PEG‐IFN add‐on for 24 weeks and 38/118
ETV Pretreatment ≥24 wks
ETV 24-48 wks
ETV 24-48 wks
PEG -IFN add-on 24-48 wks
Randomization
ETV 48 wks
Yes
No
Yes
No ETV 48 wks
Response?*
Follow-up 24 
wks
Consolidation 
24 wks
EOF
ETV Pretreatment ≥24 wks
EOT PEG-IFN End Of Consolidation**
n = 118
n = 16
n = 102
n = 2
n = 114
Follow-up 24 
wks
Consolidation 
24 wks
n = 116
25/118
93/118
7/116
109/116
HBeAg loss combined with HBV DNA <200 IU/mL? 
F IGURE 1 Combined study design. *Response: HBeAg loss in combination with HBV DNA <200 IU/mL at EOF for the intention‐to‐treat
population. **Only for responders. Non-responders were treated with ETV until EOF. Of the 32 patients who reached response at EOT, 16/25
patients assigned PEG‐IFN add‐on and 2/7 patients assigned ETV monotherapy discontinued treatment after 24 weeks of consolidation
therapy. Of these patients, 12/16 vs 2/2 patients allocated to PEG‐IFN add‐on vs ETV monotherapy sustained response at EOF. EOT, end of
treatment; EOF, end of follow‐up
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(32%) patients received PEG‐IFN add‐on for 48 weeks. Among
patients included in the ARES study, 36 non‐responders were rein-
cluded in the subsequent PEGON trial. The baseline characteristics
per trial are shown in Table S1.
3.2 | Response
Response was reached in 38/118 (33%) patients allocated to add‐on
therapy and in 23/116 (20%) patients with ETV monotherapy
(P = 0.03; Figure 2 and Table 2). Other serological, virological, and
biochemical outcomes are reported in Table 2. HBeAg seroconversion
rates at EOF were also significantly higher in PEG‐IFN add‐on
patients. The response group comprised significantly more males
(84% vs 69%, P = 0.03), and had a higher frequency of genotype B
(26% vs 13%) and fewer genotype D (12% vs 28%) compared to non‐
responders. Furthermore, responders had significantly lower ALT (0.4
vs 0.6 × ULN, P = 0.01), HBsAg (3.3 vs 3.8, P < 0.005) and HBeAg
(0.5 vs 1.4, P < 0.005) levels at baseline, and a higher frequency of
undetectable HBV DNA at baseline (53% vs 28%, P < 0.005) than
non‐responders. Other baseline characteristics were comparable
between patients with and without a response. Response occurred in
12/16 patients assigned to PEG‐IFN add‐on vs 2/2 assigned to ETV
monotherapy (P = 0.42) in the subgroup that achieved HBeAg loss in
combination with HBV DNA <200 IU/mL at EOT.
The two sensitivity analyses (cohort without 36 retreated non‐re-
sponders and whole cohort with adjustment for correlated data)
were consistent with our findings indicating that PEG‐IFN add‐on
significantly increased response to ETV monotherapy (Table S2).
3.3 | HBsAg decline and loss
HBsAg decline >0.5 log IU/mL occurred more often in the PEG‐IFN
add‐on group compared to the ETV monotherapy group at EOF (25
[23%] vs 11 [9.6%]; P = 0.01). HBsAg <1000 IU/mL was reached by
35/118 (30%) patients with PEG‐IFN add‐on and by 28/116 (24%)
with ETV monotherapy (P = 0.32) at EOT, which increased to 27% at
EOF in both groups (P = 0.97). The proportions of patients with
HBsAg <100 IU/mL in PEG‐IFN add‐on vs ETV monotherapy were 1
(1%) vs 5 (4%) at baseline (P = 0.09), and 6 (5%) vs 5 (4%) at EOF
(P = 0.77). The proportion of patients in the add‐on group with HBsAg
<100 IU/mL increased from baseline to EOF (P = 0.06). HBsAg loss
was observed in one patient assigned to PEG‐IFN add‐on.
3.4 | Sustained response after ETV discontinuation
Among the EOT responders, 16 (64%) of 25 PEG‐IFN add‐on patients
vs 2 (29%) of 7 ETV monotherapy patients discontinued ETV treat-
ment after 24 weeks of ETV consolidation therapy. The remaining
EOT responders continued ETV treatment despite response due to
protocol violations. After ETV discontinuation, 12/16 vs 2/2 patients
allocated to PEG‐IFN add‐on vs ETV monotherapy had a sustained
response (P = 0.42). Within the total cohort, response was sustained
24 weeks after stopping ETV in 12/118 (10%) vs 2/116 (0.2%)
patients assigned PEG‐IFN add‐on vs ETV monotherapy (P = 0.01).
Similarly, disease remission (combined HBeAg loss, HBV DNA
<200 IU/mL and ALT normalisation at EOF) in PEG‐IFN add‐on vs
ETV monotherapy was achieved by 12/16 vs 2/2 patients (P = 0.42).
3.5 | Response prediction
By univariable analysis, response was associated with PEG‐IFN add‐
on (odds ratio [OR] 1.9; 95% confidence interval [CI] 1.1‐3.5;
TABLE 1 Characteristics of the modified intention‐to‐treat
population at randomization
PEG‐IFN add‐on
(n = 118)
ETV
monotherapy
(n = 116)
Age, y (SD) 33 (10) 33 (9)
Male gender (%) 87 (74) 83 (72)
Ethnicity (%)
Asian 85 (72) 84 (72)
Caucasian 31 (26) 31 (27)
Other 2 (1.7) 1 (0.9)
HBV genotype (%)
A 3 (2.5) 6 (5.2)
B 22 (19) 17 (15)
C 45 (38) 51 (44)
D 30 (25) 26 (22)
Other/unknowna 18 (14) 16 (14)
Cirrhosisb (%) 3 (2.5) 5 (4.3)
Previous (PEG‐)IFN therapy (%) 16 (14) 20 (17)
ETV pretreatment (%)
6‐12 mo 80 (68) 79 (68)
1‐2 y 12 (10.2) 9 (7.9)
2‐3 y 16 (22) 28 (24)
Alanine aminotransferase, ULN (IQR) 0.5 (0.3‐0.9) 0.5 (0.4‐0.9)
HBV DNA (IU/mL) (%)
Undetectablec 38 (32) 42 (36)
20‐100 16 (14) 27 (23)
100‐1000 27 (23) 18 (16)
>1000 37 (31) 29 (25)
Quantitative HBsAg, log IU/mL (SD) 3.7 (0.7) 3.6 (0.7)
Quantitative HBeAg, log IU/mL (IQR) 1.1 (0.5‐2.0) 1.0 (0.4‐1.9)
PEG‐IFN duration (%)
24 wk 80 (68) —
48 wk 38 (32) —
IQR, interquartile range; SD, standard deviation; ULN, upper limit of nor-
mal.
aHBV genotyping was not possible for 32 patients (all Asian) due to
undetectable HBV DNA at randomization.
bCirrhosis was defined as Ishak stage 6 on liver biopsy; all 81 patients
with unavailable biopsy data had an APRI. Score <1.0, which suggests
absence of cirrhosis.
c<20 IU/mL.
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P = 0.03), male gender (OR 2.3; 95% CI 1.1‐4.9; P = 0.03), HBV
genotype (P = 0.02), lower ALT (OR 0.3; 95% CI 0.1‐0.7; P = 0.01),
lower HBV DNA level (OR 0.5; 95% CI 0.3‐0.7; P < 0.005), and
lower HBsAg level at baseline (OR 0.4; 95% CI 0.2‐0.6; P < 0.005;
Table 3). The duration of ETV pretreatment was associated with
HBsAg and HBV DNA at baseline (both P < 0.005), but not with
response (1‐3 years vs 0‐1 year, OR 1.1; 95% CI 0.6‐2.2; P = 0.76),
nor was duration of the PEG‐IFN add‐on regimen (P = 0.92). In mul-
tivariable analysis, PEG‐IFN add‐on remained independently associ-
ated with response (OR 2.5; 95% CI 1.3‐4.8; P = 0.01, when
adjusted for HBV DNA and HBsAg level at baseline). Response rates
to PEG‐IFN add‐on compared to ETV monotherapy increased espe-
cially in PEG‐IFN naive patients with lower serum HBV DNA and
HBsAg at baseline (Figure S1).
3.6 | Response‐guided therapy using HBV DNA and
HBsAg
To establish clinical starting rules for PEG‐IFN add‐on, the relation-
ship between different cut‐off values of HBsAg and HBV DNA at
baseline and likelihood of response was evaluated (Figure S2 and
Table S3). As previous use of PEG‐IFN was strongly associated with
a lack of response, we evaluated all PEG‐IFN naive patients (198/
234 [85%]). Based on this analysis, PEG‐IFN naive patients with an
HBsAg level below 4000 IU/mL (3.6 log) and HBV DNA level below
50 IU/mL (1.7 log) at baseline achieved the largest gain in probability
of response with PEG‐IFN add‐on compared to ETV monotherapy
(70% vs 34%, P = 0.01; Figure 3). Patients who met one of the
above criteria achieved a moderate gain in response from PEG‐IFN
add‐on, compared to ETV monotherapy (44% vs 17%; P = 0.02).
Above the proposed HBsAg and HBV DNA cut‐off levels, response
was very low and not significantly different between treatment
groups (PEG‐IFN add‐on vs ETV monotherapy: 9.3% vs 5.9%;
P = 0.58). The cut‐off values combined had an AUC of 0.79 (95% CI
0.72‐0.86) for probability of response.
4 | DISCUSSION
In this combined analysis of two global RCTs, PEG‐IFN add‐on to
ETV increased response compared to ETV monotherapy in HBeAg
positive patients with CHB. Response was 33% for add‐on patients
vs 20% for ETV monotherapy. HBeAg seroconversion rates at EOF
were also significantly higher in add‐on patients. The response to
PEG‐IFN add‐on was especially high (up to 70%) among patients
who were naive to PEG‐IFN therapy and had low HBV DNA
(<50 IU/mL) and HBsAg levels (<4000 IU/mL) at the start of PEG‐
IFN therapy.
TABLE 2 Outcome over time in 234 HBeAg positive patients
n (%)
Baseline
Randomization
P
End of PEG‐IFN
Week 24‐48
P
End of
consolidation
Week 72
P
End of follow‐up
Week 96
P
PEG-IFN
add-on
ETV
Mono
PEG-IFN
add-on
ETV
Mono
PEG-IFN
add-on
ETV
Mono
PEG-IFN
add-on
ETV
Mono
n = 118 n = 116 n = 118 n = 116 n = 118 n = 116 n = 118 n = 116
Response
HBeAg loss + HBV
DNA <200 IU/mL
─ ─ ─ 25 (21) 7 (6.0) <0.005* 35 (30) 15 (13) <0.005* 38 (33) 23 (20) 0.03*
Virological outcomes
HBV DNA
<2000 IU/mL
89 (75) 92 (79) 0.48 111 (95) 100 (86) 0.02* 104 (89) 102 (88) 0.82 99 (85) 104 (90) 0.24
HBV DNA <200 IU/mL 64 (54) 75 (65) 0.11 102 (87) 88 (76) 0.03* 93 (80) 92 (79) 0.97 95 (82) 97 (84) 0.62
HBV DNA
undetectablea
38 (32) 41 (35) 0.61 37 (32) 41 (35) 0.55 37 (32) 41 (35) 0.55 36 (31) 40 (35) 0.54
Serological outcomes
HBeAg loss ─ ─ ─ 25 (22) 7 (6.0) <0.005* 36 (32) 15 (13) <0.005* 40 (36) 23 (20) 0.01*
HBeAg seroconversion ─ ─ ─ 19 (16) 2 (1.7) <0.005* 26 (22) 5 (4.3) <0.005* 28 (24) 11 (9.6) <0.005*
HBsAg loss 0 (0.0) 0 (0.0) NS 1 (0.8) 0 (0.0) NS 1 (0.8) 0 (0.0) NS 1 (0.8) 0 (0.0) NS
HBsAg <1000 IU/mL 22 (19) 22 (19) 0.95 35 (30.0) 28 (24) 0.32 33 (28) 32 (28) 0.92 31 (27) 31 (27) 0.97
HBsAg <100 IU/mL 1 (0.8) 5 (4.3) 0.09 10 (8.5) 4 (3.4) 0.10 6 (5.1) 4 (3.4) 0.53 6 (5.2) 5 (4.3) 0.77
HBsAg decline
>0.5 log IU/mL
─ ─ ─ 30 (26) 2 (1.7) <0.005* 30 (26) 6 (5) <0.005* 25 (23) 11 (9.6) 0.01*
Biochemical outcome
ALT normalisation 96 (81) 90 (78) 0.56 73 (63) 94 (82) <0.005* 104 (91) 98 (86) 0.21 103 (92) 99 (86) 0.16
NS, not significant.
a<20 IU/mL.
*P < 0.05.
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This is the first study demonstrating a higher response in
patients allocated to PEG‐IFN add‐on compared to ETV monother-
apy. The strengths of this study are inclusion of a large multiethnic
cohort of patients comprising treatment naive and experienced
patients who after ETV treatment did not reach HBeAg seroconver-
sion. These patients are representative of the majority of treatment
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)
21% 20%P < 0.005*
P < 0.005*
6%
13%
33%
PEG-IFN add-on
ETV treatment 
30%
PEG-IFN
add-on
(n = 118)
P = 0.03*
ETV
monotherapy
(n = 116)
F IGURE 2 Response. *P < 0.05. Of 32
patients who reached combined HBeAg
loss and HBV DNA <200 IU/mL at week
48, 18 discontinued treatment after ETV
consolidation therapy. EOT, end of
treatment; EOF, end of follow‐up
TABLE 3 Logistic regression on response at end of follow‐up
Variable
Univariable regression Multivariable regression
OR 95% CI P‐value OR 95% CI P‐value
Age, y 1.02 0.99‐1.05 0.24
Gender, male vs female 2.31 1.09‐4.90 0.03* NS
HBV genotype 0.02* NS
C Reference
A vs C 1.50 0.35‐6.47 0.59
B vs C 2.09 0.95‐4.59 0.07
D vs C 0.43 0.17‐1.07 0.07
Other vs C 1.44 0.61‐3.37 0.41
Cirrhosis 1.76 0.41‐7.59 0.45
Duration of ETV, mo 0.79
0‐1 yr Reference
1‐3 yr vs 0‐1 yr 1.12 0.56‐2.23 0.76
>3 yr vs 0‐1 yr 1.28 0.46‐3.54 0.64
PEG‐IFN experienced vs naive 0.64 0.27‐1.56 0.33
PEG‐IFN duration, 12 vs 6 mo 0.96 0.41‐2.20 0.92
PEG‐IFN add‐on, compared to ETV monotherapy 1.92 1.06‐3.49 0.03*
Within PEG‐IFN naive 3.72 1.76‐7.87 <0.005*
Within PEG‐IFN experienced 0.24 0.04‐1.66 0.15
ALT, × ULN 0.32 0.14‐0.74 0.01* NS
HBV DNA (IU/mL)a <0.005* 0.02*
Undetectable Reference 1.00
20‐100 vs undetectable 0.67 0.30‐1.49 0.33 0.62 0.26‐1.47
100‐1000 vs undetectable 0.53 0.24‐1.17 0.12 0.47 0.19‐1.16
>1000 vs undetectable 0.10 0.03‐0.29 <0.005* 0.12 0.04‐0.42
HBsAg, log IU/mL 0.38 0.24‐0.60 <0.005* 0.51 0.29‐0.89 0.02*
NS, not significant; ULN, upper limit of normal.
aHBV DNA groups: <lower limit of detection (<20 IU/mL); 20‐100 IU/mL; 100‐1000 IU/mL; ≥1000 IU/mL.
*P < 0.05.
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eligible patients seen in clinical practice who would otherwise con-
tinue NA therapy for longer duration. A finite PEG‐IFN add‐on regi-
men offers disease remission and discontinuation of treatment,
thereby preventing additional costs and the potential of nonadher-
ence and resistance associated with long‐term or indefinite NA ther-
apy.
To avoid unnecessary side‐effects and costs of PEG‐IFN it is
essential to identify the optimal candidates for add‐on therapy as
only a subset will respond. The current HBV clinical practice guideli-
nes only broadly mention the usefulness of quantifying HBV DNA
and HBsAg to decide when and in whom to start PEG‐IFN. Evidence
to support one cut‐off value over another is limited.26,27 We estab-
lished clinical starting rules for PEG‐IFN add‐on based on widely
available biomarkers. Based on results from this study, we recom-
mend starting PEG‐IFN add‐on in PEG‐IFN naive patients with an
HBsAg level below 4000 IU/mL (3.6 logs) and HBV DNA below
50 IU/mL (1.7 log) at randomization. A sufficiently large subgroup
(28% of PEG‐IFN naive patients) had laboratory levels below these
thresholds. PEG‐IFN add‐on response rates were nearly twice as
high as the average PEG‐IFN response in previous studies.15,16 In
patients with values below either of the cut‐off values, PEG‐IFN
add‐on should be considered, as these patients have a moderately
high response to PEG‐IFN. PEG‐IFN add‐on is not recommended in
patients with both HBsAg and HBV DNA levels above the cut‐off
values, because of the low probability of response. Our HBsAg
threshold is concordant with a threshold found in another study
which showed that HBsAg <1500 IU/mL predicted response.28
Moreover, the higher and thus more lenient HBsAg cut‐off value
established in this study would allow practitioners to identify even
more candidates for PEG‐IFN add‐on at an earlier stage in their dis-
ease course. None of the previous add‐on studies provided a com-
prehensive grid search to establish response‐guided therapy. Apart
from response, the side effects and cost‐effectiveness should to be
taken into consideration when deciding on a treatment strategy.
In recent RCTs that compared PEG‐IFN add‐on to continuing NA
monotherapy, HBsAg decline rates were significantly higher in the
add‐on group, yet the primary endpoints (HBsAg loss at week 96;
combined HBeAg loss with HBV DNA <200 IU/mL at week 96) were
not reached, potentially due to a type II error.21–23 In the ARES
study response was achieved in 19% of patients in the add‐on arm
vs 10% in the monotherapy arm (P = 0.095); declines in HBsAg,
HBeAg, and HBV DNA were also larger in the add‐on group (all
P < 0.001).21 Uncontrolled studies in HBeAg positive and negative
patients reported similar findings.29,30
HBsAg 
<4,000 IU/mL
Recommendation
Response
HBV DNA 
<50 IU/mL
Yes No
PEG-IFN add-on
not recommended
Yes
PEG-IFN add-on
recommended
PEG-IFN: 70%
ETV: 34%
OR (95%CI): 2.2 (1.1-4.2)
P = 0.01
ETV-treated HBeAg positive chronic hepatitis B
PEG-IFN naive
N = 198/234
n = 82
(41%)
n = 55
(28%)
No
n = 116 
(59%)
PEG-IFN: 9.3%
ETV: 5.9%
OR (95%CI): 1.0 (0.9-1.2)
P = 0.58
Baseline
PEG-IFN add-on
should be considered
PEG-IFN: 44%
ETV: 17%
OR (95%CI): 1.5 (1.1-2.1)
P = 0.02
No Yes
n = 27
(14%)
n = 39
(20%)
n = 77
(39%)
F IGURE 3 Algorithm for probability of response at end of follow‐up based on HBV DNA and HBsAg at baseline
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The PEGAN study in HBeAg negative patients did not find a sig-
nificant effect of PEG‐IFN add‐on on HBsAg loss at week 96, but
was possibly underpowered and included older‐generation NAs.22
This study showed that PEG‐IFN add‐on treatment resulted in signifi-
cantly greater HBsAg declines and, within patients who received a
full 48 week course, larger proportions of HBsAg loss, and serocon-
version. Within patients with an HBsAg titre below 3 log IU/mL at
baseline, 6/26 (23%) achieved HBsAg loss (full dose analysis). The
PEGAN study suggested using add‐on only in patients with baseline
HBsAg levels of less than 3 log IU/mL. Other regimens of PEG‐IFN
and NA therapy, such as sequential or combination therapy have
been evaluated in CHB, but the optimal strategy remains unclear.28,31
The optimal duration of ETV pretreatment or PEG‐IFN add‐on
therapy has not yet been established. Prolonged NA pretreatment
partially restores immune function (NK and T cells).17–20 In our study
the duration of ETV pretreatment correlated to baseline HBV DNA
and HBsAg, but not to response. This suggests that levels of HBsAg
and HBV DNA at the start of PEG‐IFN therapy are more important
in considering which patients to treat than the actual duration of
ETV pretreatment. The duration of PEG‐IFN add‐on treatment did
not correlate with response. A post hoc analysis in a previous study
revealed larger HBsAg decline after 24 weeks of PEG‐IFN add‐on to
ETV therapy compared to 52 weeks of combined PEG‐IFN and LAM
therapy.32 This suggests that a PEG‐IFN course of 24 weeks is at
least as effective as 52 weeks, while the shorter regimen would
reduce the risk of IFN‐related adverse events and treatment costs.
Our analysis lacked a comparison to PEG‐IFN monotherapy. How-
ever, the focus of this study was to investigate PEG‐IFN add‐on in
the large population of patients currently on NAs, and not treatment
naive patients. Furthermore, the relation between the type of PEG‐
IFN (a2a or a2b) and the respective PEG‐IFN add‐on trials could
potentially have influenced response rates.
The endpoint of HBeAg seroclearance is clinically relevant
because it is associated with a lower risk of HCC and improved sur-
vival.9 Since only a subset of patients stopped ETV therapy after
receiving consolidation therapy the durability of sustained response
after treatment discontinuation could not be studied in further detail.
Long‐term follow‐up studies could focus on the effect on HBsAg loss
or development of important clinical outcomes (decompensation,
HCC and death), although such studies will be difficult to perform.
Due to the fact that part of the patients had received long‐term
HBV suppressive therapy HBV genotype and cirrhosis status was
not known for some patients. Nevertheless, the sensitivity analyses
performed to adjust for these partially missing baseline characteris-
tics also showed higher response and HBsAg decline achieved by
PEG‐IFN add‐on compared to ETV monotherapy. It is important that
our findings will be validated in new PEG‐IFN add‐on studies.
In conclusion, PEG‐IFN add‐on to ETV therapy was associated
with a higher probability of response and HBeAg seroconversion com-
pared to ETV monotherapy in HBeAg‐positive CHB. Response was
highest in patients who were naive to PEG‐IFN therapy with levels of
HBsAg below 4000 IU/mL and HBV DNA below 50 IU/mL. In particu-
lar these patients should be offered PEG‐IFN add‐on therapy.
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